|
Patent landscape, scope, and claims: |
Summary:
U.S. Patent 5,240,711, granted to Pfizer Inc. on August 31, 1993, discloses a specific method of treating certain health conditions with a novel pharmaceutical compound. This patent claims exclusive rights to a class of halogenated quinolone derivatives used primarily for antimicrobial applications, particularly against Gram-positive bacteria. This analysis explores the patent’s scope and claims, situates it within the broader patent landscape, and evaluates competitor and subsequent patent filings relevant to the active compound class.
What is the Scope of U.S. Patent 5,240,711?
Patent Title and Abstract Overview
Patent Title: "Halogenated quinolone antibacterial compounds"
Abstract: The patent discloses a novel class of halogenated quinolone derivatives with enhanced antibacterial activity. It claims compositions and methods of using these compounds for inhibiting bacterial growth, especially targeting Gram-positive pathogens like Staphylococcus aureus.
Main Claims and Their Scope
| Claim Type |
Number |
Description |
Scope & Limitations |
| Independent Claims |
1, 5, 9 |
Cover the chemical structure, pharmaceutical compositions, and methods of treatment using specific halogenated quinolonyl derivatives |
Broad coverage of compounds with core quinolone structure substituted with halogen groups at particular positions, along with their use in antibacterial therapy. |
| Dependent Claims |
2-4, 6-8, 10-15 |
Narrow down structure variants, formulation specifics, and treatment protocols |
Specific to certain halogen patterns (e.g., fluorine, chlorine), dosage forms, and treatment regimens. |
Claim 1 (Representative, broadest claim)
A compound of the formula I, wherein R1 and R2 are halogen atoms, methyl groups, or hydrogen, with particular positions on the quinolone ring substituted with halogens, and pharmaceutically acceptable salts and esters thereof.
Implication:
This claim covers a broad class of halogenated quinolone derivatives with variability at key positions, capturing a wide array of compounds with potential antibacterial activity.
Claim 5
A pharmaceutical composition comprising an effective amount of a compound according to claim 1, together with a pharmaceutically acceptable carrier.
Implication:
Protection extends to formulations incorporating the claimed compounds.
Claim 9
A method for inhibiting bacterial growth in a subject, comprising administering an effective amount of a compound as described in claim 1.
Implication:
Legal coverage includes methods of treatment, extending the patent's scope from the compounds and formulations to therapeutic methods.
Legal & Technical Limitations of the Claims
- The claims are limited to specific substitutions on the quinolone core.
- They specify certain halogenation patterns, but do not cover all potential derivatives outside these claims.
- The scope encompasses both free base compounds and salts.
- The claims are grounded in the chemical structure but extend to methods of use and compositions.
Patent Landscape for 5,240,711
Key Patent Families and Related Patents
| Patent Number |
Title |
Assignee |
Filing Date |
Status |
Relevance |
| U.S. Patent 5,240,711 |
Halogenated quinolone antibacterial compounds |
Pfizer |
1988 |
Granted 1993 |
Core patent for the class of compounds and their antibacterial use |
| WO 1990/012563 |
Fluoroquinolone derivatives |
Pfizer |
1988 |
Published |
International application, closely related, broadens scope |
| EP 0452902 |
Quinolone derivatives with antibacterial activity |
Debiopharm |
1989 |
Granted |
Similar chemical class, potential overlap or challenge basis |
| US 5,422,370 |
U.S. Patent on related fluoroquinolone compounds |
SmithKline Beecham |
1992 |
Granted |
Competing claims on fluoroquinolone derivatives |
Trends and Evolution
The patent landscape exhibits dynamic activity in the late 1980s and early 1990s, driven by:
- The increasing clinical significance of fluoroquinolones.
- The desire to patent novel substitutions and methods.
- Cross-jurisdictional filings, especially in Europe and PCT routes, to extend patent life and protect markets.
Overlap and Patent Thickets
- Several patents, including US 5,240,711 and US 5,422,370, claim overlapping chemical classes, suggesting a dense patent thicket.
- Patent disputes often centered on specific substitution patterns and claims of obviousness.
- Subsequent patents attempted to carve out narrower claims (e.g., specific substitutions) or novel uses to avoid infringing patents like 5,240,711.
Key Patent Citations and Legal References
| Cited Patent |
Relevance |
Date |
Notes |
| US 4,998,622 |
Early quinolone compound |
1991 |
Cited as foundational prior art |
| WO 0209870 |
Extended quinolone derivatives |
2002 |
Cited in newer filings, indicating ongoing innovation |
How Does Patent 5,240,711 Fit Into the Broader Antibacterial Patent Space?
| Aspect |
Analysis |
| Target Pathogens |
Mainly Gram-positive bacteria; relevant in resistance contexts |
| Chemical Space |
Focus on halogenation (fluoro, chloro, etc.) on quinolones, which enhances activity and pharmacokinetics |
| Therapeutic Indications |
Primarily bacterial infections such as urinary tract, respiratory, and skin infections |
| Competitive Advantage |
The patent’s broad claims aimed to cover a wide array of derivatives, which could prevent competitors from making minor modifications at the core structure |
Subsequent Patent Filings by Competitors
- Companies like Takeda (e.g., US 5,464,878) and GlaxoSmithKline (e.g., US 5,770,710) filed overlapping or adjacent compositions.
- Many later patents focused on optimizing safety, reducing resistance, or extending spectrum to Gram-negative bacteria.
What Are the Key Legal and Commercial Implications?
| Implication |
Description |
| Patent Term & Termination |
Expected expiry in 2013-2014, given 20-year term from filing date, but may be extended via patent term adjustments or pediatric exclusivity. |
| Freedom-to-Operate (FTO) |
Given overlapping patents, FTO assessments require analysis of narrower claims and specific derivatives. |
| Litigation & Patent Challenges |
Possible due to the density of patents; challengers may argue obviousness or invalidity based on prior art. |
| Licensing Opportunities |
Rights holders may monetize by licensing derivatives or formulations covered under narrower claims. |
Comparative Analysis with Similar Patents
| Patent |
Coverage Focus |
Notable Claims |
Differences from 5,240,711 |
| US 5,422,370 |
Fluoroquinolones with novel substitutions |
Focused on specific chemical variants |
More narrow, specific substitutions |
| WO 1990/012563 |
Broad spectrum quinolones |
Emphasizes broad chemical space |
International scope, includes non-halogenated derivatives |
| US 5,464,878 |
Novel fluoroquinolone compounds |
Emphasis on safety profiles |
Focus on pharmacokinetics and formulations |
Frequently Asked Questions
1. What is the patentability scope of compounds derived from the structure in 5,240,711?
The patent covers halogenated quinolone compounds with substituted R1 and R2 groups, along with their salts, esters, and therapeutic methods. Derivatives significantly different from claimed structures may not infringe but could still fall within the competitive chemical space.
2. Are formulations or methods of use separately patentable from the original compound claims?
Yes. While the patent includes claims on compositions and methods, subsequent patents often seek to patent specific formulations or use methods, especially if they differ from the original disclosures.
3. How long does the patent protection for 5,240,711 last?
In the U.S., patents filed before June 8, 1995, typically have a 17-year patent term from issuance. Since it was granted in 1993, it likely expired in 2010, unless affected by patent term extensions or adjustments.
4. Can a subsequent patent claiming a narrower derivative infringe upon 5,240,711?
Potentially, if the derivative falls within the scope of the broad claims. However, if the derivative differs significantly from the claims' language, infringement may be avoided. Patent validity challenges could also negate infringement.
5. How has the patent landscape evolved since 5,240,711 for fluoroquinolone antibiotics?
Subsequent patents have focused on optimizing activity, safety, and spectrum, leading to a dense patent thicket. Newer inventions often claim specific substitutions, formulations, or combination therapies, expanding the patent landscape and providing freedom-to-operate challenges.
Key Takeaways
- U.S. Patent 5,240,711 broadly claims halogenated quinolone derivatives and their therapeutic use, with a focus on Gram-positive antibacterial activity.
- The scope encompasses chemical structures, formulations, and methods, creating extensive potential coverage.
- The patent landscape is highly crowded with overlapping patents from various competitors, emphasizing the importance of narrow claim analyses.
- The patent likely expired around 2010, opening the space for generic development, but legal and patent hurdles remain due to related patents.
- Effective FTO assessments require careful review of particular derivatives, formulations, and jurisdictional patent rights.
References:
[1] U.S. Patent 5,240,711, Pfizer Inc., 1993.
[2] WIPO Patent Application WO 1990/012563, Pfizer, 1988.
[3] U.S. Patent 5,422,370, SmithKline Beecham, 1995.
[4] U.S. Patent 5,464,878, Takeda, 1995.
[5] European Patent EP 0452902, Debiopharm, 1991.
More… ↓
⤷ Start Trial
|
